News
NEXI
3.465
-0.73%
-0.026
Weekly Report: what happened at NEXI last week (0415-0419)?
Weekly Report · 4h ago
NEXI Stock Earnings: NexImmune Reported Results for Q4 2023
NexImmune just reported results for the fourth quarter of 2023. The company did not report any revenue for the quarter. NexImmune reported earnings per share of -$4.99 and no revenue at the quarter's end. InvestorPlace Earnings is a project that automates coverage of quarterly earnings.
Investorplace · 5d ago
Neximmune, Inc. Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Press release · 5d ago
Weekly Report: what happened at NEXI last week (0408-0412)?
Weekly Report · 04/15 10:39
Weekly Report: what happened at NEXI last week (0401-0405)?
Weekly Report · 04/08 10:42
NexImmune Announces Leadership Shift in Financial Management
TipRanks · 04/05 20:24
NEXIMMUNE INC: APPOINTED ALBERT N. MARCHIO II AS INTERIM CFO
Reuters · 04/05 20:08
XXII, GRIN and XTIA are among mid-day movers
On the Move XXII, GRIN and XTIA are among mid-day movers. MediaCo Holding and 22nd Century Group are among the biggest gainers. NewGenIvf, Kenon and HWH are among those losing ground in the biotech sector.
Seeking Alpha · 04/05 18:55
BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Arch Capital, US energy sector
Wall Street's main stock indexes rose on Friday after a strong jobs report. Top three S&P 500 percentage gainers: Constellation Energy, Newmont and GE Aerospace. The top three NYSE percentage losers: Tesla, Arch Capital and Carnival. Arch Capital up on $450 million deal to buy some US insurance businesses.
Reuters · 04/05 17:56
Weekly Report: what happened at NEXI last week (0325-0329)?
Weekly Report · 04/01 10:41
Weekly Report: what happened at NEXI last week (0318-0322)?
Weekly Report · 03/25 10:44
Weekly Report: what happened at NEXI last week (0311-0315)?
Weekly Report · 03/18 10:42
Weekly Report: what happened at NEXI last week (0304-0308)?
Weekly Report · 03/11 10:40
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
HighPeak Energy, Inc. Shares fell 15.3% to $13.49 on Thursday. The company reported worse-than-expected fourth-quarter revenue results. Lytus Technologies Holdings PTV. Ltd. Shares jumped 404% in the mid-day session.
Benzinga · 03/07 18:35
Rentokil Initial, Avangrid, American Eagle Outfitters among premarket gainers' pack
Rentokil Initial, Avangrid, American Eagle Outfitters among premarket gainers' pack. Lytus Technologies +210% after entering $326 billion data center market. Honest Company +33% after reporting a profit in Q4. CERo Therapeutics +625% after preclinical research supporting use of clinical candidate to treat AML patients.
Seeking Alpha · 03/07 14:09
Weekly Report: what happened at NEXI last week (0226-0301)?
Weekly Report · 03/04 10:42
Weekly Report: what happened at NEXI last week (0219-0223)?
Weekly Report · 02/26 10:52
NexImmune Has Received A Decision To Grant European Patent Number EP3970748 Titled "Nanoparticle Compositions And Methods For Immunotherapy"
Benzinga · 02/20 16:38
12 Health Care Stocks Moving In Monday's After-Market Session
Trexade Health (NASDAQ:MEDS) stock rose 105.3% to $8.5 during Monday's after-market session. Iovance Biotherapeutics shares moved upwards by 32.78% during the session. Virpax Pharmaceuticals and Delcath Systems were the biggest losers in the company.
Benzinga · 02/19 21:30
Weekly Report: what happened at NEXI last week (0212-0216)?
Weekly Report · 02/19 10:53
More
Webull provides a variety of real-time NEXI stock news. You can receive the latest news about Neximmune, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About NEXI
NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML) and NEXI-002 in multiple myeloma (MM). The Company provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The Company’s T cell product candidates are designed to combine the attributes of cellular with reduced potential for toxicities. It is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.